Prescribing patterns of allopurinol and febuxostat according to directives on the reimbursement criteria and clinical guidelines: analysis of a primary care database

References

• Richette P, Bardin T. Gout. Lancet 2010;375:318–28
   PubMed Web of Science ®Google Scholar
• Hui M, Carr A, Cameron S, et al. The British Society for Rheumatology guideline for the management of gout. Rheumatology 2017;56:1246.
   PubMedGoogle Scholar
• Neogi T. Clinical practice. Gout. N Engl J Med 2011;364:443–52
   PubMed Web of Science ®Google Scholar
• Campion EW, Glynn RJ, Delabry LO. Asymptomatic hyperuricemia. Risks and consequences in the normative aging study. Am J Med 1987;82:421–6
   PubMedGoogle Scholar
• Roddy E, Zhang W, Doherty M. The changing epidemiology of gout. Nat Clin Pract Rheumatol 2007;3:443–9
   PubMedGoogle Scholar
• Trifirò G, Morabito P, Cavagna L, et al. Epidemiology of gout and hyperuricaemia in Italy during the years 2005–2009: a nationwide population-based study. Ann Rheum Dis 2013;72:694–700
   PubMed Web of Science ®Google Scholar
• Kuo C-F, Grainge MJ, Zhang W, et al. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol 2015;11:649–62
   PubMed Web of Science ®Google Scholar
• George RL, Keenan RT. Genetics of hyperuricemia and gout: implications for the present and future. Curr Rheumatol Rep 2013;15:309
   PubMed Web of Science ®Google Scholar
• Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 2017;76:29–42
   Google Scholar
• Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American college of rheumatology guidelines for management of gout. part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 2012;64:1431–46
   Web of Science ®Google Scholar
• Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American college of rheumatology guidelines for management of gout. part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res 2012;64:1447–61
   Web of Science ®Google Scholar
• Ernst ME, Fravel MA. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout. Clin Ther 2009;31:2503–18
   PubMed Web of Science ®Google Scholar
• Italian Medicines Agency (Agenzia Italiana del Farmaco AN 91). Nota 91. IMA; 2010. Available at: http://www.agenziafarmaco.gov.it/it/content/nota-91 [Last accessed April 25, 2018]
   Google Scholar
• Lawrenson R, Williams T, Farmer R. Clinical information for research; the use of general practice databases. J Public Health Med 1999;21:299–304
   PubMedGoogle Scholar
• Gijsen R, Poos MJJC. Using registries in general practice to estimate countrywide morbidity in The Netherlands. Public Health 2006;120:923–36
   PubMed Web of Science ®Google Scholar
• Fleming DM, Schellevis FG, Van Casteren V. The prevalence of known diabetes in eight European countries. Eur J Public Health 2004;14:10–14
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index. WHO; 2018. Available at: http://www.whocc.no/atc_ddd_index/ [Last acessed April 20, 2018)
   Google Scholar
• Guglielmi V, Bellia A, Bianchini E, et al. Drug interactions in users of tablet vs oral liquid levothyroxine formulations: a real-world evidence study in primary care. Endocrine 2018;59:585–92
   PubMed Web of Science ®Google Scholar
• Cricelli C, Mazzaglia G, Samani F, et al. Prevalence estimates for chronic diseases in Italy: exploring the differences between self-report and primary care databases. J Public Health Med 2003;25:254–7
   PubMedGoogle Scholar
• Riedel AA, Nelson M, Joseph-Ridge N, et al. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol 2004;31:1575–81
   PubMed Web of Science ®Google Scholar
• Mantarro S, Capogrosso-Sansone A, Tuccori M, et al. Allopurinol adherence among patients with gout: an Italian general practice database study. Int J Clin Pract 2015;69:757–65
   PubMed Web of Science ®Google Scholar
• Stamp LK. Safety profile of anti-gout agents: an update. Curr Opin Rheumatol 2014;26:162–8
   PubMed Web of Science ®Google Scholar
• Arellano F, Sacristan JA. Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother 1993;27:337–43
   PubMed Web of Science ®Google Scholar
• Lang PG. Severe hypersensitivity reactions to allopurinol. South Med J 1979;72:1361–8
   PubMed Web of Science ®Google Scholar
• Singer JZ, Wallace SL. The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality. Arthritis Rheum 1986;29:82–7
   PubMed Web of Science ®Google Scholar
• Tausche AK, Aringer M, Schroeder HE, et al. The Janus faces of allopurinol-allopurinol hypersensitivity syndrome. Am J Med 2008;121:e3–4.
   PubMed Web of Science ®Google Scholar
• Ryu HJ, Song R, Kim HW, et al. Clinical risk factors for adverse events in allopurinol users. J Clin Pharmacol 2013;53:211–16
   Google Scholar
• Jones G, Panova E, Day R. Guideline development for the management of gout: role of combination therapy with a focus on lesinurad. Drug Des Devel Ther 2017;11:3077–81
   PubMed Web of Science ®Google Scholar
• Dalbeth N, Stamp L. Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events. Semin Dial 2007;20:391–5
   PubMed Web of Science ®Google Scholar
• Doherty M, Jansen TL, Nuki G, et al. Gout: why is this curable disease so seldom cured? Ann Rheum Dis 2012;71:1765–70
   PubMed Web of Science ®Google Scholar
• Perez-Ruiz F, Martínez-Indart L, Carmona L, et al. Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Ann Rheum Dis 2014;73:177–82
   PubMed Web of Science ®Google Scholar
• White WB, Saag KG, Becker MA, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med 2018;378:1200–10
   PubMed Web of Science ®Google Scholar
• Stamp LK, Chapman PT, Barclay ML, et al. A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Ann Rheum Dis 2017;76:1522–8
   PubMed Web of Science ®Google Scholar